| Literature DB >> 28976598 |
Danijela Stojanović1, Petra Bůžková2, Kenneth J Mukamal3, Susan R Heckbert4,5,6, Bruce M Psaty4,5,6, Howard A Fink7,8, Jane A Cauley9, Erin Wallace10, Lesley H Curtis11, Calvin Hirsch12, Matthew Budoff13, Dong Li14, Rebekah Young2, Diana Jalal15, Joseph Ac Delaney6,16.
Abstract
Several in vitro and animal studies have showed that inflammatory markers play a role in bone remodeling and pathogenesis of osteoporosis. Additionally, some human longitudinal studies showed suggestive associations between elevated inflammatory markers and increased risk of nontraumatic fractures. We examined several inflammatory markers and multiple fracture types in a single study of older individuals with extensive follow-up. We assessed the association of four inflammatory markers with the risk of incident hip fractures among 5265 participants of the Cardiovascular Health Study (CHS) and a composite endpoint of incident fractures of the hip, pelvis, humerus, or proximal forearm in 4477 participants. Among CHS participants followed between 1992 and 2009, we observed 480 incident hip fractures during a median follow-up of 11 years. In the composite fracture analysis cohort of 4477 participants, we observed 711 fractures during a median follow-up of 7 years. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for hip fracture associated with doubling of IL-6 were HR 1.15 (95% CI, 1.02 to 1.30) overall and HR 1.17 (95% CI, 1.01 to 1.35) in women. We also observed a positive association between each unit increase in white blood cell (WBC) count and risk of hip fracture: HR 1.04 (95% CI, 1.01 to 1.06) overall and HR 1.06 (95% CI, 0.95 to 1.20) in women. We observed no significant associations between any of the four inflammatory markers and a composite fracture endpoint. Our findings suggest that chronic inflammatory and immune processes may be related to higher rates of incident hip fractures.Entities:
Keywords: CYTOKINES; FRACTURE RISK ASSESSMENT; GENERAL POPULATION STUDIES; OSTEOIMMUNOLOGY
Mesh:
Substances:
Year: 2017 PMID: 28976598 PMCID: PMC5809254 DOI: 10.1002/jbmr.3301
Source DB: PubMed Journal: J Bone Miner Res ISSN: 0884-0431 Impact factor: 6.741